Skip to content

Neuroplasticity: all studies

Page 99 of 178: studies 981 to 990 of 1,772, newest first. Back to the neuroplasticity overview

Research

EMBODIED WISDOM: INTEGRATING YOGA, BREATH, AND KINESTHETIC LEARNING IN EDUCATION

August 9, 2025 Himani Kaushik Avi Choudhary

This chapter explores the profound connection between yoga, conscious breathing, and kinesthetic learning, advocating for an embodied approach to knowledge acquisition and self-development. It posits that learning is not solely a cognitive process but is deeply rooted in physical experience. The chapter details how yoga, as an embodied pedagogy, enhances body awareness, motor skills, and the...

DOI: 10.25215/1257861093.14 (opens in new tab) Embodied cognition Kinesthetic learning Cognitive science Pedagogy +1

Intersecting Psychedelic Pharmacology and Gut-Brain Axis Signaling in Neurodegenerative Disorders

JUNIOR RESEARCHERS August 8, 2025 Harsha S. Krishna

Neurodegenerative diseases are marked by progressive neuronal loss, inflammation, and impaired plasticity. Although existing treatments provide limited protection for the brain or ability to slow disease progression, emerging research highlights the gut-brain axis and psychedelics as promising new areas for therapeutic development. The gut microbiome, a metabolically active ecosystem,...

Substance Abuse and Cognitive Decline: The Critical Role of Tau Protein as a Potential Biomarker

International Journal of Molecular Sciences August 7, 2025 Liliana Rebolledo-Pérez, Jorge Hernández‐bello, Alicia Martínez-ramos et al. 5 citations

Tau protein is essential for the structural stability of neurons, particularly through its role in microtubule assembly and axonal transport. However, when abnormally hyperphosphorylated or cleaved, Tau can aggregate into insoluble forms that disrupt neuronal function, contributing to the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD). Emerging evidence suggests...

DOI: 10.3390/ijms26157638 (opens in new tab) Biomarker Cognition Cognitive decline

Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat

Frontiers in Psychiatry August 6, 2025 Grace Blest‐hopley, Giuseppe Pasculli, Simon Ruffell et al. 3 citations

Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effects, promoting neuroplasticity and reorganising functional connectivity across cortical and subcortical networks involved in emotion and cognition. Veterans with traumatic brain injuries (TBI) often experience chronic neurological and psychological...

Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models

Frontiers in Systems Neuroscience August 5, 2025 Dotun Adeleye Adeyinka, Donelson R. Forsyth, Suzanne Currie et al. 7 citations

Psilocybin, a compound found in Psilocybe mushrooms, is emerging as a promising treatment for neurodegenerative and psychiatric disorders, including major depressive disorder. Its potential therapeutic effects stem from promoting neuroprotection, neurogenesis, and neuroplasticity, key factors in brain health. Psilocybin could help combat mild neurodegeneration by increasing synaptic density and...

Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects

Frontiers in Psychiatry August 4, 2025 Fernando Mora, J. Ramos-Quiroga, Enrique Baca-García et al. 5 citations

Introduction Depression is a highly prevalent disease that severely impacts the life of patients. Inadequate response to at least two antidepressants despite adequacy of treatment and adherence is known as treatment-resistant depression (TRD), which entails a higher social and economic burden than non-resistant major depression. The lack of consensus on the definition of TRD and other aspects...

544. MOLECULAR AND CELLULAR MECHANISMS OF THE LONG-LASTING EFFECTS OF PSYCHEDELICS AND THEIR NON-HALLUCINOGENIC DERIVATIVES

The International Journal of Neuropsychopharmacology August 1, 2025 Argel Aguilar-Valles, Dhiral Kot, Vern Lewis et al.

Abstract Background Major depressive disorder (MDD) is a multifactorial and heterogeneous disorder that affects around 280 million individuals worldwide, with approximately 80 million experiencing treatment-resistant depression (TRD). Neuronal hypotrophy and axon hypomyelination in the prefrontal cortex (PFC) are hallmark features of MDD, highlighting the need for treatments that address these...

Enhanced Modulation of CaMKII in Mouse Hippocampus by an Antidepressant-like Dose of Melatonin/Ketamine Combination

Cells August 1, 2025 Armida Miranda-Riestra, Rosa Estrada-Reyes, Luis A Constantino-Jonapa et al.

Forty per cent of major depression patients are resistant to antidepressant medication. Thus, it is necessary to search for alternative treatments. Melatonin (N-acetyl-5-hydroxytryptamine) enhances neurogenesis and neuronal survival in the adult mouse hippocampal dentate gyrus. Additionally, melatonin stimulates the activity of Ca2+/Calmodulin-dependent Kinase II (CaMKII), promoting dendrite...

Ayahuasca-Induced Serotonin Syndrome: Risks, Mechanisms, and Clinical Considerations

Pharmaceutical Science August 1, 2025 Melissa Ortega

Ayahuasca is a traditional Amazonian brew composed primarily of Banisteriopsis caapi and Psychotria viridis, drawing increasing interest for its psychedelic effects and potential therapeutic applications. Its pharmacological action is based on the synergistic combination of β-carbolines (harmine, tetrahydroharmine, and harmaline), which act as reversible inhibitors of monoamine oxidase A...

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review.

Cureus August 1, 2025 Brett Hughes, Soz Mirza, Manasi Ponamala et al.

The stresses of the Coronavirus Disease of 2019 (COVID-19) pandemic highlighted the burden of psychiatric disorders within the pediatric population, revealing a pre-existing need for rapid-onset therapies that have since driven efforts to expand effective therapeutic interventions. In this narrative review, we utilized the Preferred Reporting Items for Systematic reviews and Meta-Analysis...